CRSP logo

CRSP
CRISPR Therapeutics AG

41,295
Mkt Cap
$5.01B
Volume
2.94M
52W High
$78.48
52W Low
$30.04
PE Ratio
-10.16
CRSP Fundamentals
Price
$55.56
Prev Close
$56.61
Open
$53.61
50D MA
$62.93
Beta
1.61
Avg. Volume
2.64M
EPS (Annual)
-$4.34
P/B
2.85
Rev/Employee
$94,946.57
Loading...
Loading...
News
all
press releases
CRISPR Therapeutics AG $CRSP Shares Acquired by Vestmark Advisory Solutions Inc.
Vestmark Advisory Solutions Inc. lifted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 115.3% in the second quarter, according to the company in its most recent...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a -2.56% change from its previous close.
Zacks·22h ago
News Placeholder
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $9.00 by Analysts at Wedbush
Wedbush lowered their price target on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an "outperform" rating on the stock in a report on Wednesday...
MarketBeat·1d ago
News Placeholder
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
Zacks·3d ago
News Placeholder
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
Zacks·4d ago
News Placeholder
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.
Zacks·5d ago
News Placeholder
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?
CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.
Zacks·5d ago
News Placeholder
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Zacks·8d ago
News Placeholder
CRISPR Therapeutics AG (CRSP) Stock Moves -2.51%: What You Should Know
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $62.56, representing a -2.51% change from its previous close.
Zacks·10d ago
News Placeholder
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·10d ago

Latest CRSP News

View

Advertisement|Remove ads.

Advertisement|Remove ads.